Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD30 CAR-T + nivolumab
- Development stage
- Unknown
- Lead developer
- Tessa Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Autologous CD30 CAR-T + nivolumab is an investigational combination therapy consisting of autologous T cells engineered to express a chimeric antigen receptor (CAR) targeting CD30 (commonly known as TT11) administered together with the anti-PD-1 monoclonal antibody nivolumab. The combination is being studied primarily for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL) after failure of frontline therapies. The rationale is that PD-1 blockade with nivolumab may enhance the persistence and antitumor activity of CD30-CAR-T cells by alleviating T-cell exhaustion in the immunosuppressive microenvironment characteristic of cHL[2][3][4][1].
- Brand names
- TT11TT-11TT 11
- Other names
- autologous CD30.CAR-T cells + nivolumabCD30.CAR-T + nivolumabTT11 + nivolumabautologous CD30 CAR-T cells in combination with nivolumab
02
Targets
CD30 (CD30 antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on autologous CD30 CAR-T + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD30 CAR-T + nivolumab.